Rokote Laboratories is set to launch a nasal spray vaccine utilising specialised gene transfer technology by Academy Professor Seppo Ylä-Herttuala’s research group. The technology has been successfully used in several clinical trials to treat cardiovascular diseases and cancer.
Nasal administration was chosen as the delivery method because the virus is transmitted through the airways. Also, the research group assumes that the method can prevent those who have received the vaccine from transmitting the virus.
Academy Professor Ylä-Herttuala, one of the founders of Rokote Laboratories, pointed out that the need to develop vaccines doesn’t disappear despite the current vaccination campaigns, as new variants are expected to cause new waves of infections.
Rokote Laboratories Finland Ltd., is a newly-founded, Finnish academic spin-out. University of Helsinki and University of Eastern Finland are shareholders in the company.